secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPLASH BEVERAGE GROUP, INC. (SBEV)
CIK:        0001553788
Form:       8-K
Filed at:   2026-07-06T12:46:06+00:00
Accession:  0001731122-26-000910
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Splash Beverage acquires exclusive global rights to CannEpil epilepsy therapy from Argent BioPharma
--------------------------------------------------------------------------------

- Exclusive global license for CannEpil, a cannabinoid-based therapy for drug-resistant epilepsy already used in Europe.
- Consideration includes $1M investment from C/M Capital, $5M debt forgiveness, and $5.5M preferred equity issuance.
- Argent BioPharma to receive 15% royalty on net revenue from worldwide sales of CannEpil.
- CannEpil has FDA pre-IND engagement and an IND number for U.S. clinical development.
- Drug-resistant epilepsy affects ~30% of epilepsy patients; therapy has EU-GMP manufacturing and European patient access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226000910/0001731122-26-000910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226000910/e7759_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer